Clinical Trial Update: A Study of MET233 in Individuals With Obesity or Overweight [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for MET233 in adults with obesity or overweight, spanning Phase 1 and Phase 2, sponsored by Metsera (a Pfizer subsidiary), currently not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• MET233

Snippet

Sponsor: Metsera, a wholly owned subsidiary of Pfizer | Conditions: Obesity and Overweight | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING